Company Profile
Intellia Stock Price, News & Analysis
Company overview
Business overview
Intellia Therapeutics is a gene-editing company focused on in vivo CRISPR-based medicines. Investors watch how the platform translates into durable clinical proof, delivery confidence, and a broader pipeline.
Geographic Base and Sector Classification
Headquartered in Cambridge, Massachusetts and listed on NASDAQ, Intellia is followed within the gene-editing universe for its exposure to platform milestones and clinical execution.
Business Model Characteristics
Intellia is a platform-led story, so the market focuses on delivery, durability, and whether each update expands confidence in the gene-editing approach.
Position Within the Biotechnology Landscape
Compared with commercial-stage biotech peers, Intellia sits at the development end of the landscape, where gene-editing timing can move valuation quickly.
Why the stock is moving
NTLA is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Intellia's catalysts are NTLA-2001 in ATTR, NTLA-2002 in hereditary angioedema, and the broader in vivo CRISPR editing platform. The company still needs clinical proof that its one-time-editing approach can translate into a repeatable therapeutic business.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.